or Try an Advanced Search...

    Therapies For Cancer Stocks List

    Symbol Grade Name % Change
    CRGX B CARGO Therapeutics, Inc. 4.46
    PMCB B PharmaCyte Biotech, Inc. 1.10
    ALLO D Allogene Therapeutics, Inc. 6.46
    VOR D Vor Biopharma Inc. -4.17
    ARTV D Artiva Biotherapeutics, Inc. 5.72
    GALT F Galectin Therapeutics Inc. 1.21
    CGEM F Cullinan Management, Inc. 1.48
    BDTX F Black Diamond Therapeutics, Inc. 5.47
    ACET F Adicet Bio, Inc. -2.34
    NKTX F Nkarta, Inc. 3.57
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Cancer Biotechnology Immune System Tumor Antigen Cancer Immunotherapy Medicine Acute Myeloid Leukemia Adoptive Cell Transfer Antibodies Biopharmaceutical Cancer Treatment Cell Therapy Chimeric Antigen Receptor Chimeric Antigen Receptor T Cell Clinical Medicine Gene Therapy Tyrosine Kinase Receptors Alcohol Biology

    Related ETFs - A few ETFs which own one or more of the above listed Therapies For Cancer stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 4.83
    BBC B Virtus LifeSci Biotech Clinical Trials ETF 1.36
    MEDX D Horizon Kinetics Medical ETF 1.06
    CANC C Tema Oncology ETF 0.83
    WDNA D WisdomTree BioRevolution Fund 0.58
    View all Therapies For Cancer ETFs...
    Compare ETFs
    Compare CNCR to BBC Compare CNCR to CANC Compare CNCR to WDNA

        Therapies For Cancer Stocks Recent News

        Date Stock Title
        Nov 1 ALLO Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline
        Nov 1 BDTX Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
        Oct 31 NKTX Nkarta (NKTX) Stock: Looking For Upside
        Oct 31 ALLO Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know
        Oct 31 NKTX Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)
        Oct 30 ALLO Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
        Oct 29 ALLO Allogene receives FDA RMAT designation for its metastatic renal cell carcinoma treatment
        Oct 29 ALLO We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
        Oct 29 ALLO Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Cancer Biotechnology Immune System Tumor Antigen Cancer Immunotherapy Medicine Acute Myeloid Leukemia Adoptive Cell Transfer Antibodies Biopharmaceutical Cancer Treatment Cell Therapy Chimeric Antigen Receptor Chimeric Antigen Receptor T Cell Clinical Medicine Gene Therapy Tyrosine Kinase Receptors Alcohol Biology
        Therapies For Cancer

        Therapies for cancer can include a variety of treatments, such as surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy. Depending on the type and stage of cancer, a combination of these treatments may be used. Other treatments, such as hormone therapy, stem cell transplantation, and cryotherapy, may also be used.

        Browse All Tags